1、 Suqawara K, Takahashi H, Kashiwaquara T, et al. Effect of Anti-inflammatory supplementation with whey peptide and exercise therapy in patients with COPD[J]. Respiratory Medicine, 2012(106): 1526-1534. Suqawara K, Takahashi H, Kashiwaquara T, et al. Effect of Anti-inflammatory supplementation with whey peptide and exercise therapy in patients with COPD[J]. Respiratory Medicine, 2012(106): 1526-1534.
2、 Hanaoka J,Shimada M,Utsunvmiya T,et al. Beneficial effects of enteral nutrition containing with hydrolyzed whey peptide on warm ischemia/reperfusion injury in the rat liver[J]. Hepatology Research, 2013(44): 114-21. Hanaoka J,Shimada M,Utsunvmiya T,et al. Beneficial effects of enteral nutrition containing with hydrolyzed whey peptide on warm ischemia/reperfusion injury in the rat liver[J]. Hepatology Research, 2013(44): 114-21.
3、 Seidner DL,Lashner BA,Brzezinski A,et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial[J]. Clinical Gastroenterology and Hepatology, 2005, 3(4): 358-369. Seidner DL,Lashner BA,Brzezinski A,et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial[J]. Clinical Gastroenterology and Hepatology, 2005, 3(4): 358-369.
4、 Niess JH,Danese S.Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology[J]. Gut,2014(63): 533-5. Niess JH,Danese S.Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology[J]. Gut,2014(63): 533-5.
5、 Targownik LE, Bernstein C. Infectious and malignant complications of TNF inhibitor therapy in IBD[J]. The American Journal Of Gastroenterology, 2013(108):1835-1842. Targownik LE, Bernstein C. Infectious and malignant complications of TNF inhibitor therapy in IBD[J]. The American Journal Of Gastroenterology, 2013(108):1835-1842.
6、 Vande Casteele, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015(148): 1320-1329. Vande Casteele, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015(148): 1320-1329.
7、 Ngo B,Farrell CP,Barr M,et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety[J]. Current Molecular Pharmacology, 2010(3):145-52. Ngo B,Farrell CP,Barr M,et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety[J]. Current Molecular Pharmacology, 2010(3):145-52.
8、 Ebach DR,Newberry R,Stenson WF, Differential role of tumor necrosis factor receptors in TNBS colitis[J]. Inflammatory bowel diseases, 2006, 11(6): 533-540. Ebach DR,Newberry R,Stenson WF, Differential role of tumor necrosis factor receptors in TNBS colitis[J]. Inflammatory bowel diseases, 2006, 11(6): 533-540.
9、 Saiki TU,Mitsuyama K,Toyonaga A, et al, Detection of pre-and anti-inflammatory cytokines in stool of patient with inflammatory bowel[J]. Scand J Gastroenterol, 1999, 33(67): 616-622. Saiki TU,Mitsuyama K,Toyonaga A, et al, Detection of pre-and anti-inflammatory cytokines in stool of patient with inflammatory bowel[J]. Scand J Gastroenterol, 1999, 33(67): 616-622.
10、 欧阳钦.炎症性肠病发病机制与治疗研究的最新进展[J]. 中华消化杂志, 2003, 23(8): 453-454. 欧阳钦.炎症性肠病发病机制与治疗研究的最新进展[J]. 中华消化杂志, 2003, 23(8): 453-454.
11、 张涛,谢建群. 大鼠溃疡性结肠炎模型的实验研究[J]. 中国中西医结合消化杂志, 2006, 14(4): 240-241. 张涛,谢建群. 大鼠溃疡性结肠炎模型的实验研究[J]. 中国中西医结合消化杂志, 2006, 14(4): 240-241.
